Johnson & Johnson unit settles patent dispute over hypertension drug
In a win for Johnson & Johnson, its Actelion unit has settled an infringement lawsuit after generic drug maker Laurus conceded that a patent for a pulmonary hypertension drug was valid.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 January 2017 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision that said patent claims owned by Ethicon, a subsidiary of Johnson & Johnson (J&J), are invalid.
29 January 2014 Healthcare company Covidien PLC has been told it did not infringe patents belonging to a Johnson & Johnson-owned company through using its ultrasonic dissection device.